---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-000342"
form_type: "8-K"
ticker: "ZIVO"
cik: "0001101026"
company_name: "Zivo Bioscience, Inc."
filed_at: "2022-01-11T23:59:59+00:00"
generated_at: "2026-06-27T18:50:50.290243+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ZIVO Bioscience terminates CEO Andrew Dahl; Chairman John Payne named President and CEO

## Summary
- Andrew A. Dahl terminated as President and CEO on January 4, 2022.
- John B. Payne, previously Chairman, appointed President and CEO effective January 7, 2022.
- Payne founded Compassion-First Pet Hospitals; served as President and CEO until 2020.
- Payne removed from Compensation and Audit Committees; Christopher Maggiore appointed.
- Company highlights 2021 progress including Nasdaq uplisting; expects seamless transition.

## SEC filing metadata
- accession: 0001654954-22-000342
- form_type: 8-K
- ticker: ZIVO
- cik: 0001101026
- company_name: Zivo Bioscience, Inc.
- filed_at: 2022-01-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1101026/000165495422000342/0001654954-22-000342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1101026/000165495422000342/zivo_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-000342
- JSON: https://secwatch.observer/filing/0001654954-22-000342.json
- Plain text: https://secwatch.observer/filing/0001654954-22-000342.txt

## Key facts
- Executive change
  John B. Payne was appointed as President and Chief Executive Officer at Zivo Bioscience, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: Effective as of January 7, 2022, the Board of the Company appointed Mr. John B. Payne as the Company’s President and Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1101026/000165495422000342/0001654954-22-000342-index.htm
- Executive change
  Andrew A. Dahl was terminated as President and Chief Executive Officer at Zivo Bioscience, Inc..
  - Action: terminated
  - Role: President and Chief Executive Officer
  source text: On January 4, 2022, Zivo Bioscience, Inc. (the “Company” ) terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1101026/000165495422000342/0001654954-22-000342-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.